Smad3 and Smad4 protein complex (mediating TGF-β signaling) (Smad3/Smad4 (sometimes Smad3-Smad4 complex))

The Smad3/Smad4 signaling pathway refers to the *canonical intracellular route* by which TGF-β receptors modulate gene transcription. Upon TGF-β ligand binding, the receptor phosphorylates Smad3, which then forms a complex with Smad4. This complex translocates to the nucleus, binds target DNA elements, and controls transcription of genes involved in cell cycle regulation, apoptosis, development, and immune function[1][3][4][5][7]. Smad4, also known as *Deleted in Pancreatic Cancer Locus 4*, operates as a tumor suppressor and is frequently inactivated in cancers[5][3]. Disruption of Smad3 or Smad4 function or expression is implicated in multiple malignancies and developmental syndromes. In summary: The term "Smad3/Smad4 signaling pathway" refers to a pathway, not a unique molecular target; the correct targets are Smad3 and Smad4 proteins. Smad3 and Smad4 are transcription factors central to TGF-β-mediated gene regulation, implicated in cancer, fibrosis, and development. Direct therapeutic targeting of this pathway is typically achieved by modulating TGF-β or its receptor, not by drugs directly binding Smad3/Smad4. Smad4 mutations and loss are key biomarkers in oncology[3][5]. Targeting the pathway carries safety challenges due to TGF-β’s broad biological effects[5][3][1].

Other names

Smad3-Smad4 complexSmad3/Smad4 heteromeric complexTGF-β-induced Smad complex

Inhibition of TGF-β receptor blocks phosphorylation/activation of Smad3/Smad4, reducing fibrotic or tumor-promoting signaling. Some experimental drugs target Smad-dependent transcription to modulate disease.